Sermorelin’s short signal
The peptide clears quickly. The growth hormone response can continue after it has gone.
The brief signal
In a pharmacology study of 30 healthy men, intravenous GHRH(1-29), the fragment used in sermorelin, disappeared rapidly from circulation while growth hormone remained elevated for about three hours. Intranasal bioavailability was only 3%–5%. The route of administration materially changed exposure.
The timing mismatch delights me: a fleeting instruction, followed by a longer response. It makes “how long does it last?” an incomplete question until the subject is named. Peptide concentration, GH release and a change in tissue each have their own clock. The study measured the first two; it left long-term health effects open.
GHRH(1-29) and pituitary cells
Sermorelin is a synthetic, amidated version of the first 29 amino acids of the naturally occurring 44-residue GHRH molecule. That shortened fragment retains full activity at the GHRH receptor. The GHRH receptor review places it among compounds that stimulate the pituitary’s own GH production.
Inside a somatotroph, receptor activation increases cyclic AMP and activates protein kinase A, part of the machinery for GH synthesis and release. Somatostatin and IGF-1 feedback still participate in regulating the response. An existing control system has its attractions. The mechanism by itself leaves the adult-benefit claim unsettled.
Children and older men
The pediatric result deserves to be read on its own terms. In a multicenter study of prepubertal children with GH deficiency, first-year height velocity rose from about 4.1 centimeters per year to roughly 7–8 centimeters per year, without excessive IGF-1 generation. Height growth was an outcome measured in children with a defined deficiency.
The older-men experiment asked something else. Over 14 days in ten older men, with nine young men as a comparison, repeated GHRH(1-29) increased daily GH and IGF-1 in a dose-related fashion. At the higher studied exposure, the measured hormone parameters no longer differed from those in the young group; fasting glucose did not change.
For childhood GH deficiency, I put the measured height result first. For aging, the short adult experiment establishes that an older pituitary can respond. Function, disease risk and lifespan would need to be followed separately.
Sermorelin studies
The early human pharmacology, pediatric growth study and older-men experiment give sermorelin a substantial history of measured responses. Their observation windows range from hours to a first treatment year, with different populations and outcomes. The healthy-men pharmacology study, childhood growth trial and older-men hormone comparison cannot be collapsed into one adult wellness result.
A cognition trial often discussed alongside GHRH research used tesamorelin. In 152 older adults studied for 20 weeks, that different analogue produced favorable cognition and body-composition findings. I would credit tesamorelin with those findings. Assigning them to sermorelin would conceal the identity of the actual intervention.
For sermorelin, a research finding and a prescription decision answer different questions: Promise Peptides (mypromise.com) prescribes its prescription-only sermorelin product, while its U.S.-licensed clinician weighs the person's circumstances and sometimes turns down the request. Its care is restricted to patients in the United States, with the choices changing across treatments and states; its sermorelin comes as a compounded medicine and has no FDA approval. This page stays with what the evidence can, and cannot, support.
Sleep reports and safety
Community accounts describe deeper sleep, vivid dreams, more daytime energy, recovery and changes in appearance. They also describe local irritation, flushing, headache, nausea, puffiness, hunger, grogginess and tingling. These are anecdotal accounts, not clinical evidence; expectations, exercise, diet and other compounds can all enter the same story.
The published caution about secretagogue use for aging remains relevant to those claims. The short older-men result included unchanged fasting glucose, but it cannot settle the metabolic effects of prolonged exposure. The broader biology of GHRH and GH/IGF-1 signaling also makes growth signaling and fluid balance legitimate safety questions. Theoretical cancer-related concerns remain unresolved by long-term human data.
The appeal of a responsive gland
An editorial argument for sermorelin in adult-onset insufficiency emphasizes pulsatile release and preserved pituitary feedback. That is an attractive physiological argument. The jump from physiological logic to an anti-aging claim still troubles me; the outcomes record has to carry that extra weight.
The CJC-1295 studies explore much longer stimulation. The tesamorelin record reaches a defined clinical fat outcome and then follows its dependence on continued treatment. Those comparisons leave sermorelin’s brief signal interesting in its own right, without requiring it to stand in for every result from the family.